Amplify Weight Loss Drug & Treatment ETF (THNR) price, chart and fund profile
Price chart
Fund profile
THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.
- Issuer
- Amplify Investments
- Industry
- Healthcare
- Inception
- May 21, 2024
- Expense ratio
- 0.59%
- Net asset value
- $26.97
- NAV as of
- Aug 28, 2026
- Leverage
- 1×
- Fund page
- amplifyetfs.com↗
Frequently asked questions
What is Amplify Weight Loss Drug & Treatment ETF (THNR)?
THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.
What is THNR's expense ratio?
Amplify Weight Loss Drug & Treatment ETF charges an annual expense ratio of 0.59%. The fund is issued by Amplify Investments.
How large is THNR?
Amplify Weight Loss Drug & Treatment ETF manages $5.4M in assets and has traded since May 21, 2024.
How do I buy shares of Amplify Weight Loss Drug & Treatment ETF (THNR)?
THNR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.